Home » Newsletters » BioWorld Science

BioWorld Science

March 15, 2019

View Archived Issues

LIDDS begins phase I study of intratumoral NanoZolid combined with docetaxel for solid tumors

Identification of a novel immunotherapy target to treat myeloid blood cancers

Analysis identifies key bacterial virulence gene

DermBiont initiates phase II study of DBI-001 for the treatment of athlete's foot

Veverimer phase III results for metabolic acidosis associated with chronic kidney disease

ABBV-151 enters first-in-human study

Scholar Rock names TGF-beta1 activation inhibitor for further development

Targeting AhR for treating age-related macular degeneration proven useful

Bayer presents CHICO phase III results for nifurtimox in pediatric Chagas disease

FP-101 relieves hot flashes in menopausal women and women taking tamoxifen

ImmunogenX initiates phase II study of latiglutenase for celiac disease

Fujian Institute of Research on the Structure of Matter presents interferon modulators

Jiangsu Chia Tai Tianqing Pharmaceutical Group and others patent TRK inhibitors

Asceneuron discovers N-acetyl-beta-D-glucosaminidase inhibitors

Acesion Pharma identifies new SK (Ca) 2.3 channel blockers

New PIK3C3 and authophagy inhibitors synthesized at Sprint Bioscience

Phase I/II study planned for ACT-107 after first-in-human results show safety

Sutro initiates phase I study of STRO-002 in ovarian and endometrial cancers

Spectrum withdraws BLA for Rolontis with plans to resubmit

BCL9 targeting impacts intestinal neoplasia pathogenesis

Recreating lineage-specific cardiac cells from iPSCs

Antibodies to mosquito saliva offer Zika protection

Protein kinase C inhibitor LXS-196 studied in uveal melanoma patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...